News Releases

ITUS Subsidiary Anixa Diagnostics Corporation Appoints Dr. Michael Shepard to Its Scientific Advisory Board

December 7, 2015

ITUS Subsidiary Anixa Diagnostics Corporation Announces Initial Cancer Biomarker Results

October 5, 2015

ITUS Subsidiary Anixa Diagnostics Enters Into Collaborative Research Agreement With The Wistar Institute, a Leading Cancer Research Institute

July 14, 2015

ITUS Announces Uplisting to NASDAQ

July 9, 2015

ITUS Announces Reverse Stock Split With the Intention to List Shares on NASDAQ

June 25, 2015

ITUS Announces Formation of Cancer Diagnostics Subsidiary

June 23, 2015

ITUS Releases Operating Results for Fiscal 2014

January 29, 2015

Latest News & Events

Jan 6, 2020

Anixa Biosciences Announces Presentation at AACR Liquid Biopsies Conference

Read More...

Dec 23, 2019

Anixa Biosciences to Present at Biotech Showcase 2020

Read More...

Dec 16, 2019

Anixa Biosciences Announces Commercial Launch of Cchek™ Prostate Cancer Confirmatory Test

Read More...

Cancer of the Lung, Breast, Colon, Prostate, and Stomach are the five most prevalent cancers worldwide.